Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6.

Pier Giorgio CojuttiAngela LonderoPaola Della SiegaFilippo GivoneMartina FabrisJessica BiasizzoCarlo TasciniFederico Pea

Published in: Clinical pharmacokinetics (2020)

This is a proof-of-concept of SARS-CoV-2 disease-drug interactions, and may support the need for optimal dose selection of sensitive CYP3A4 substrates in severe SARS-CoV-2 patients.

Keyphrases

sars cov
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
hepatitis c virus
hiv infected
hiv aids